Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer

Cancer Biology and Therapy

Volumn 5, Issue 10, 2006, Pages 1355-1356

  Zangemeister Wittke, Uwe ^a   Huwiler, Andrea ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apoptosis; Drug resistance; Gastric cancer; Mcl 1 antisense

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIM PROTEIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; OBLIMERSEN; PROTEIN A1; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INCIDENCE; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; DOWN REGULATION; DRUG BINDING; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MELANOMA; NOTE; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; STOMACH CANCER; TUMOR GROWTH;

EID: 33751112991     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.10.3488     Document Type: Note

References (13)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30.
2. Haglund UH, Wallner B. Current management of gastric cancer. J Gastrointest Surg 2004; 8:907-14.
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108:153-64.
4. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays 2000; 22:1007-17.
5. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116:205-19.
6. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17:393-403.
7. Green DR. At the gates of death. Cancer Cell 2006; 9:328-30.
8. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19:1294-305.
9. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, Deconti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG. Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738-45.
10. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13:1351-9.
11. Maeta Y, Tsujitani S, Matsumoto S, Yamaguchi K, Tatebe S, Kondo A, Ikeguchi M, Kaibara N. Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer 2004; 7:78-84.
12. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001; 93:463-71.
13. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24:6861-9.